Project description
AI for lung fluid congestion monitoring
Heart failure (HF) is one of the most frequent causes of hospitalisation and premature death around the world. Patients who survive HF and return home need to remain under continuous monitoring so that any complications from lung fluid congestion are immediately treated. Unfortunately, these are often diagnosed very late. The EU-funded ReDS project is developing a medical device enabling easy, quick monitoring of lung congestion from the patient's home. It's non-invasive, connected with an artificial intelligence-based platform that manages collected data and sends it automatically to the care-centre. A special algorithm helps the doctor to prescribe proper treatment according to a patient's situation.
Objective
Heart failure (HF) is one of the main causes of mortality and hospitalization worldwide, affecting around 26M people globally, and the most common cause of hospitalization for people over 65. Lung fluid congestion is one of the main HF-related clinical conditions, which leads to a vicious cycle of repeated hospitalizations of HF patients. Strikingly, 1 in 4 patients are readmitted to the hospital within 30 days, and 1 in 2 patients within 6 months. The key challenge is to enable early detection, continuous monitoring and timely treatment of symptoms before the patient undergoes respiratory distress. In fact, current lung fluid monitoring practices are mostly inaccurate and inefficient, enabling detection only at very advanced stages, when symptoms cannot be prevented by simply changing the medication.
Sensible introduces ReDS™, a non-invasive home monitoring system for lung fluid congestion in HF patients. The monitoring procedure can be performed by the patient at home in just 90 seconds. The results are processed by an Artificial Intelligence (AI)-driven patient management platform and sent automatically to the physician. The unique proprietary AI algorithm supports physicians in identifying the best treatment based on each patients’ needs and general health status. ReDS™ is the first solution that enables accurate, remote monitoring and management of fluid congestion in HF patients after discharge.
During the phase 1 feasibility study, Sensible will define a minimum viable product, establish a sound go-to-market strategy and supply chain, and draft further development plans. During the second phase of the innovation project, Sensible will optimize the device engineering for home use, optimize the AI algorithm, scale-up device manufacturing and perform clinical validation with partner hospitals.
Fields of science
- natural sciencescomputer and information sciencesartificial intelligence
- social sciencessociologydemographymortality
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsradio technologyradar
- medical and health sciencesclinical medicinecardiology
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
4059300 NETANYA
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.